Posts by Cyril H. Benes, PhD
-
Combined EGFR/FGFR Inhibitor Therapy Proposed for FGFR2-Positive Intrahepatic Cholangiocarcinoma
By analyzing patient-derived models of FGFR2 fusion–positive intrahepatic cholangiocarcinoma, scientists at the Mass General Cancer Center determined feedback activation of EGFR-dependent signaling limits the efficacy of FGFR inhibitors and combined EGFR/FGFR inhibition may be a therapeutic solution.
Biography
Cyril H. Benes, PhD, is principal investigator of the Benes Lab at the Mass General Cancer Center of Massachusetts General Hospital.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
